Warnex Medical Laboratories and Epigenomics have entered into a non-exclusive licensing agreement for Epigenomics' colorectal cancer biomarker Septin9.
Under the terms of the agreement, Warnex has obtained the rights to establish a laboratory developed test for Septin9 and offer colorectal cancer blood testing services in Canada.
Warnex plans to launch the testing service in the next few months, Epigenomics will be entitled to certain royalty payments.
Further contractual details were not disclosed.
In numerous studies with more than 3,300 blood samples, Epigenomics has demonstrated that methylated DNA of the Septin9 gene in blood plasma is a reliable indicator of colorectal cancer of all stages and all locations.
This paved the way for a convenient blood test for colorectal cancer early detection that can easily be integrated into the patient's routine physical, is non-invasive and does not require any drug or dietary restrictions.
